No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Corcept Therapeutics Inc. is a pharmaceutical company focused on the research, development, and commercialization of treatments for severe metabolic, oncologic, and neuropsychiatric disorders within the United States. Their primary commercial product, Korlym (mifepristone) tablets, is an oral medication administered once daily. It targets hyperglycemia stemming from hypercortisolism in adult patients with endogenous Cushing's syndrome, particularly those with type 2 diabetes or glucose intolerance who have either failed or are unsuitable for surgical intervention. The company's developmental pipeline includes relacorilant, which is being advanced for Cushing's syndrome treatment. A combination therapy of nab-paclitaxel and relacorilant has completed Phase II clinical trials for advanced ovarian tumors and is also under investigation for managing cortisol excess. Further endeavors involve a selective cortisol modulator for metastatic castration-resistant prostate cancer, another selective cortisol modulator for antipsychotic-induced weight gain and other conditions, and the development of FKBP5 gene expression assays. Corcept Therapeutics Inc. was founded in 1998 and has its headquarters in Menlo Park, California.
www.corcept.comNo one on the platform currently holds 0I3Q.L.
No tracked institution reports a position in 0I3Q.L as of their last filing.
No one on the platform has traded 0I3Q.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.5% | 23.7% | 50.3% | — | — | — |
| Rev. Growth % | 12.8% | 16.6% | ||||
| Profit Margin % | 13.1% | 22.3% | 29.3% | |||
| Free Cash Flow Margin % | 18.6% | 29.9% | 34.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +36.2% | $2.06 | $1.88–$2.41 | — | 1 |
| 2027 | $1.6B | +42.8% | $4.29 | $3.92–$5.01 | — | 1 |
| 2028 | $2.2B | +37.5% | $7.12 | $6.51–$8.31 | — | 1 |
| 2029 | $2.5B | +14.1% | $8.54 | $7.81–$9.97 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.02 | $0.36 | +1383.3% |
| 2026-04-30 | $-0.11 | $-0.30 | -172.3% |
| 2026-02-24 | $0.33 | $0.20 | -39.3% |
| 2025-11-04 | $0.16 | $0.16 | -1.0% |
| 2025-07-31 | $0.19 | $0.29 | +54.7% |
| 2025-05-05 | $0.14 | $0.17 | +19.3% |
| 2025-02-26 | $0.43 | $0.26 | -39.8% |
| 2024-10-31 | $0.28 |
| $0.41 |
| +45.7% |
| +0.44% |
| $15.3B |
| — |
| 0J2O.LHalozyme Therapeutics, Inc. | $108.94 | +2.27% | $12.9B | — |
| 0JZ2.LMasimo Corporation | $179.96 | +0.01% | $9.5B | — |
Source: Financial Modeling Prep · peers by sector/industry